JP5435955B2 - 安定な酵素製剤及びその使用方法 - Google Patents

安定な酵素製剤及びその使用方法 Download PDF

Info

Publication number
JP5435955B2
JP5435955B2 JP2008548072A JP2008548072A JP5435955B2 JP 5435955 B2 JP5435955 B2 JP 5435955B2 JP 2008548072 A JP2008548072 A JP 2008548072A JP 2008548072 A JP2008548072 A JP 2008548072A JP 5435955 B2 JP5435955 B2 JP 5435955B2
Authority
JP
Japan
Prior art keywords
buffer
solution
composition
kit
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008548072A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009521521A5 (https=
JP2009521521A (ja
Inventor
アミヘイ フリーマン，
ノア ハダー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of JP2009521521A publication Critical patent/JP2009521521A/ja
Publication of JP2009521521A5 publication Critical patent/JP2009521521A5/ja
Application granted granted Critical
Publication of JP5435955B2 publication Critical patent/JP5435955B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2008548072A 2005-12-27 2006-12-27 安定な酵素製剤及びその使用方法 Expired - Fee Related JP5435955B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75340005P 2005-12-27 2005-12-27
US60/753,400 2005-12-27
PCT/IL2006/001492 WO2007074454A2 (en) 2005-12-27 2006-12-27 Stable enzymatic preparations and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2009521521A JP2009521521A (ja) 2009-06-04
JP2009521521A5 JP2009521521A5 (https=) 2010-02-12
JP5435955B2 true JP5435955B2 (ja) 2014-03-05

Family

ID=37943776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008548072A Expired - Fee Related JP5435955B2 (ja) 2005-12-27 2006-12-27 安定な酵素製剤及びその使用方法

Country Status (6)

Country Link
US (2) US8197808B2 (https=)
EP (1) EP1965763B1 (https=)
JP (1) JP5435955B2 (https=)
DK (1) DK1965763T3 (https=)
ES (1) ES2763724T3 (https=)
WO (1) WO2007074454A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8197808B2 (en) 2005-12-27 2012-06-12 Ramot At Tel-Aviv University Ltd. Stable enzymatic preparations and methods of use thereof
ATE554769T1 (de) * 2006-12-06 2012-05-15 Cornell Res Foundation Inc Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
CA2727432C (en) 2008-06-12 2016-10-11 Medtronic Xomed, Inc. Method for treating chronic wounds with an extracellular polymeric substance solvating system
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
KR20170005191A (ko) 2009-01-06 2017-01-11 큐어론 엘엘씨 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
CN102300989B (zh) 2009-01-06 2015-12-09 柯尔朗恩有限责任公司 用于治疗或预防金黄色葡萄球菌感染以及用于根除或减少表面上金黄色葡萄球菌的组合物和方法
EP2226382A1 (en) 2009-03-03 2010-09-08 B.R.A.I.N. Biotechnology Research and Information Network AG Protease for wound conditioning and skin care
US8592451B2 (en) 2009-03-17 2013-11-26 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9220700B2 (en) 2009-08-19 2015-12-29 Cornell University Cysteine for physiological injection
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
SG187534A1 (en) 2010-08-29 2013-03-28 Vascode Technologies Ltd A system and methods for multi-tasking in a clientless mobile phone
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
CN107854737B (zh) * 2011-08-31 2021-03-26 凯希特许有限公司 减压治疗与清创系统以及方法
CA2862363C (en) * 2012-02-02 2021-06-08 Joan M. Fallon Enzyme compositions and use thereof for wound healing
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
AU2016340017B2 (en) * 2015-10-14 2023-10-05 Newsouth Innovations Pty Limited Compositions and methods for the treatment of diseases involving mucin
JP6952353B2 (ja) * 2016-01-31 2021-10-20 メディウーンド リミテッド 創傷を治療するためのデブリードマン組成物
BR112018071405A2 (pt) * 2016-04-18 2019-02-05 Mediwound Ltd métodos de debridamento de ferimentos crônicos
AU2018250823A1 (en) 2017-04-10 2019-10-17 Curemark, Llc Compositions for treating addiction
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
EP4251141A4 (en) * 2020-11-25 2024-10-02 Topix Pharmaceuticals, Inc. SCAR TREATMENT COMPOSITION
CN115998690B (zh) * 2022-11-10 2024-07-26 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB913203A (en) * 1958-12-30 1962-12-19 Swift & Co Enzyme formulations for the production of tenderized meat
US3539451A (en) * 1968-05-31 1970-11-10 Castle & Cooke Production of reversibly inactivated papain and ficin
US4307081A (en) * 1974-01-08 1981-12-22 Gerold K. V. Klein Enzyme mixture
US4715899A (en) * 1982-10-21 1987-12-29 Subir Chanda Liquid cleaner containing inactivated protease for protein soiled contact lenses
JPH0449299A (ja) * 1990-06-14 1992-02-18 Tosoh Corp 免疫グロブリンフラグメントの精製法
DE4026591B4 (de) 1990-08-23 2005-08-25 Pleva Gmbh Vorrichtung zur Bestimmung der Beladung von Luft mit Dämpfen
JP2665639B2 (ja) * 1992-01-09 1997-10-22 テーオー食品株式会社 安定化されたチオール蛋白分解酵素を含む焼き肉のタレ
US7364565B2 (en) 2001-07-27 2008-04-29 Ramot At Tel Aviv University Ltd. Controlled enzymatic removal and retrieval of cells
MXPA04004479A (es) * 2001-11-13 2004-08-11 Procter & Gamble Composiciones topicas que contienen enzimas estabilizadas con inhibidores.
US6692726B1 (en) * 2003-02-11 2004-02-17 Colgate Palmolive Company Enzyme containing oral composition having enhanced stability
DE602004020910D1 (de) * 2003-10-10 2009-06-10 Cosmedical Aps Haarwuchshemmung
US8197808B2 (en) 2005-12-27 2012-06-12 Ramot At Tel-Aviv University Ltd. Stable enzymatic preparations and methods of use thereof

Also Published As

Publication number Publication date
ES2763724T3 (es) 2020-05-29
EP1965763B1 (en) 2019-11-06
US8337837B2 (en) 2012-12-25
WO2007074454A2 (en) 2007-07-05
WO2007074454A3 (en) 2007-09-20
US8197808B2 (en) 2012-06-12
JP2009521521A (ja) 2009-06-04
DK1965763T3 (da) 2020-02-10
US20120114631A1 (en) 2012-05-10
US20090220483A1 (en) 2009-09-03
EP1965763A2 (en) 2008-09-10

Similar Documents

Publication Publication Date Title
JP5435955B2 (ja) 安定な酵素製剤及びその使用方法
IL192483A (en) Distribution tool for single use
Monafo et al. Topical therapy for burns
US8343515B2 (en) Perfluorocarbon gel formulations
US20210275471A1 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
KR101514414B1 (ko) 당뇨병성 족부 궤양의 치료방법
AU7176391A (en) A treatment system and method for wounds and other disorders
US20120225102A1 (en) Perfluorocarbon gel formulations
US20080020025A1 (en) Composition for wound care and method of using same
ES2785999T3 (es) Composición para su uso en la preparación de un paciente para cirugía
US9370533B2 (en) Wound healing compositions comprising microspheres
EP2877188B1 (en) Preparation for treatment of wounds and sores comprising hypochlorite and amino acids
CA2248177A1 (en) Use of protealytic enzymes in the treatment of insect bites
EP3503873A1 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
JPH01503146A (ja) 身体組織の治療方法および身体組織への医薬の投与方法
US20230338296A1 (en) Devices and methods for delivery of oxygen to a wound
RU2649785C1 (ru) Антисептическая композиция, содержащая поливинилпирролидон и унитиол, применение такой композиции и способ обработки ран с ее использованием
Burba Traumatic foot injuries in horses: surgical management
WO2007143586A2 (en) Composition for wound care and method of using same
Elmenshawy et al. Successful management after ingestion of a potentially fatal dose of inorganic mercuric chloride: A case report
Mang et al. Tumescent Technique in Aesthetic Plastic Surgery with Low Doses of Prilocaine Solution, Part I
JP2693961B2 (ja) 創傷の治癒のための二段階方法及びそれらに使用される水性媒体及び局所性軟膏
EP1776960B1 (en) Use of collagen in combination with oxygen- and ozone-releasing perfluorocarbons for the preparation of a medicament for the treatment of skin lesions
Khasukhanova et al. APPLICATION OF INTRA-AORTIC OZONATED SALINE SOLUTION AS A METHOD OF TREATMENT OF PERITONITIS
Curreri et al. Advances in the clinical care of burned patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120521

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130710

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131210

R150 Certificate of patent or registration of utility model

Ref document number: 5435955

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees